We are live on ! Find out more
KBIO

KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO

Delisted

KBIO was delisted on the 16th of December, 2015.

43 hedge funds and large institutions have $39.8M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% less funds holding

Funds holding: 4843 (-5)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

24% less capital invested

Capital invested by funds: $52.2M → $39.8M (-$12.4M)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

Holders
43
Holders Change
-5
Holders Change %
-10.42%
% of All Funds
1.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
11
Reduced
14
Closed
18
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
51
Bank of New York Mellon
New York
-$76K -3,508 Closed
Jane Street
52
Jane Street
New York
-$72K -3,344 Closed
Charles Schwab
53
Charles Schwab
California
-$64K -2,925 Closed
TCIM
54
TIAA CREF Investment Management
New York
-$63K -2,911 Closed
California State Teachers Retirement System (CalSTRS)
55
California State Teachers Retirement System (CalSTRS)
California
-$58K -2,680 Closed
ARTA
56
A.R.T. Advisors
New York
-$42K -1,946 Closed
GC
57
Guggenheim Capital
Illinois
-$33K -1,523 Closed
ProShare Advisors
58
ProShare Advisors
Maryland
-$33K -1,506 Closed
BA
59
BlackRock Advisors
Delaware
-$23K -1,047 Closed
AIG
60
American International Group
New York
-$21.9K -1,012 Closed
TA
61
Teachers Advisors
New York
-$20K -910 Closed

KBIO Hedge Fund Activity: Q2 2014 in Review

43 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q2 2014, worth a combined $39.8M — down 24% from $52.2M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of KBIO and 13 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $2.49M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $4.59M sold.

  • 43 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q2 2014, down from 48 in Q1 2014.
  • Funds reported $39.8M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q2 2014, down 24% quarter-over-quarter.
  • 13 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q2 2014 and 18 closed out, a net change of -5 holders.
  • The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q2 2014 was BVF Inc, an estimated $2.49M added.
  • The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q2 2014 was JP Morgan Chase, an estimated $4.59M sold.

Based on aggregated 13F filings for Q2 2014.